News

June 29, 2020June 30, 2020

FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials

News, syndicated

The U.S. Food and Drug Administration (FDA) has launched an initiative called Project Patient Voice to create a publicly available information bank describing patient-reported symptoms from cancer trials for marketed ... Read more

June 25, 2020June 25, 2020

Cost of Cancer Treatment in US Could Rise by 34% by 2030

News

The cost of treating acute myeloid leukemia (AML) and other cancers in the United States is projected to increase substantially by 2030, a study reports. The study, “Medical Care Costs ... Read more

June 22, 2020June 22, 2020

Genetic Testing Often Worth the Wait for More Tailored Treatments, Study Says

News

Waiting for the results of genetic tests to begin treatment for acute myeloid leukemia (AML) might allow certain patients to benefit from more tailored therapies, according to a recent study. ... Read more

June 18, 2020June 18, 2020

FDA Approves Mylotarg as First-Line AML Treatment for Children

News

Mylotarg (gemtuzumab ozogamicin) has been approved for the first-line treatment of children, ages one month or older, who have acute myeloid leukemia (AML) positive for the CD33 protein, the U.S. ... Read more

June 15, 2020June 15, 2020

Moleculin Seeks Two More Test Sites in European Annamycin Trial

News

Despite disruptions from the COVID-19 pandemic, Moleculin Biotech is aiming to expand the number of sites for clinical trials of its annamycin chemotherapy for the treatment of acute myeloid leukemia ... Read more

June 11, 2020June 11, 2020

Protocol First Wins Funding for Beat AML Clinical Trial

News

Protocol First has received a funding commitment from The Leukemia & Lymphoma Society (LLS) to help advance the Beat AML Master Clinical Trial (Beat AML), which seeks to evaluate several ... Read more

June 8, 2020June 8, 2020

Intellia Looking to Bring Its Potential T-cell Therapy for AML into Trials

News

Data from early studies suggest that Intellia Therapeutics‘s proprietary CRISPR/Cas9 technology can more effectively generate tumor targeting T-cells than conventional methods, and support testing NTLA-5001, the company’s engineered cell therapy candidate ... Read more

June 4, 2020June 4, 2020

MacroGenics Plans Registration Study of Flotetuzumab for Hard-to-treat AML Patients

News

Following discussions with the U.S. Food and Drug Administration (FDA), MacroGenics is planning for a single-arm clinical trial that supports the approval of its investigational molecule flotetuzumab for the treatment ... Read more

June 1, 2020June 1, 2020

FDA OKs Phase 1 Trial of Antibody, IO-202, to Treat Advanced AML and CMML

News

The U.S. Food and Drug Administration (FDA) has agreed to Immune-Onc Therapeutics launching a Phase 1 clinical trial of IO-202, its lead antibody treatment candidate, in patients with advanced acute myeloid leukemia ... Read more

May 28, 2020May 28, 2020

Venclexta Plus Vidaza Improves Survival for AML Patients, AbbVie Reports

News

First-line treatment with a combination of Venclexta (venetoclax) and Vidaza (azacitidine) significantly extended survival in people with acute myeloid leukemia (AML) who were ineligible for intensive chemotherapy, as compared with Vidaza alone, AbbVie ... Read more